Harnessing the power of the electrical signal of the heart to transform cardiac care through cutting-edge AI solutions
Listen to Dr. Paul Friedman, a Professor of Medicine and Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Anumana advisor, discuss the potential of AI algorithms in advancing early diagnosis and intervention in cardiology.
Serious cardiovascular diseases affect millions of people worldwide, often going undiagnosed until symptoms advance and patients deteriorate, at times resulting in life-threatening events and creating a multi-billion dollar healthcare burden. Anumana’s AI solutions enable earlier diagnosis of these otherwise hidden diseases, empowering clinicians to intervene with treatments earlier and improve outcomes.
Today, the power of AI is just beginning to be leveraged in clinical decision support and has the potential to provide immense value during interventional procedures. Anumana’s algorithms and software have the potential to improve procedure accuracy, reduce procedure times, improve medication management, and improve patient safety and outcomes.
Anumana leverages the largest combined dataset of electrophysiological data, longitudinal patient history, and outcomes in the world. This dataset was developed from multi-year, exclusive data partnerships with leading academic medical centers from Anumana’s parent company, nference. This real-world evidence generation platform, nSights, is inclusive of 11M patients spanning 20+ years and transforms unstructured data (i.e. clinical notes, echocardiogram reports) and semi-structured (i.e. lab tests, medications, appointments, etc) data into labeled data format at scale. This extensive "deep data" platform fuels Anumana's research and development.
Anumana transforms research-grade algorithms into medical devices, conducting necessary clinical validation for regulatory clearance, and working with leading clinical experts around the world. Anumana's portfolio includes dozens of first-in-class algorithms, including ECG-AI algorithms for early disease detection and EGM-AI algorithms to improve EP procedures.
Anumana builds and commercializes clinician-facing software and solutions for seamless integration of its technology into existing clinical workflows. Anumana's software solutions integrate with EMRs and other point-of-care technology used within the clinician's existing workflow.
Anumana has a robust FDA-ready pipeline of ECG-AI algorithms, with 75+ peer-reviewed publications that showcase the potential of these algorithms for early cardiovascular disease detection and improved prognosis.
Granted FDA Breakthrough Device Designation
Anumana has a highly fertile portfolio of EP applications under development, aiming to increase procedure accuracy, reduce procedure time, and improve patient safety and outcomes.
Phase: Market Authorization
See Anumana’s work in the news
Oct. 19th, 2023
Based on pioneering research from Mayo Clinic, ECG-AI LEF aims to aid physicians in identifying low ejection fraction in patients at risk of heart failure
Oct. 2nd, 2023
Developed in collaboration with Mayo Clinic, with support from Pfizer, this ECG-AI algorithm aims to aid physicians in earlier identification of cardiac amyloidosis
Jun. 21st, 2023
AI-driven startup from nference and Mayo Clinic Platform positioned to transform cardiac care
Mar. 20th, 2023
Learn more about Anumana’s algorithms validated in 75+ peer reviewed publications.
Aug. 8th, 2022
Nov. 13th, 2022
Nov. 14th, 2022
Nov. 1st, 2022
In just the past three years, the team has published more than two dozen studies on AI in cardiology, and it is now field-testing an algorithm to detect a weak heart pump in dozens of primary care clinics.
Dec. 18th, 2019
Featuring key corporate highlights and an overview of Anumana's technology